My primary research focus is to use a powerful novel insertional mutagen, the Sleeping Beauty (SB) transposon system, to address fundamental questions in cancer genetics. My training has previously focused on developing SB for forward genetic screens for cancer genes in mice. In my own research laboratory, I would like to pursue additional experiments studying the role of genes identified by SB in the context of human cancer, initially focusing on the BRAF oncogene. In addition, I would like to adapt the SB system to elucidate the genetics of a fundamental problem in human cancer treatment, namely therapy resistance. I propose to use the SB system to identify genes that are involved in acquired resistance to BAY 43-9006, a kinase inhibitor now showing promise in clinical trials as a chemotherapeutic agent. In addition, I propose to use the SB system to identify genes involved in prostate cancer progression as a result of acquired insensitivity to hormone ablation therapies. The role of identified genes in therapy resistance will be tested in human cancer models. These projects will be initiated in my final year as a post-doctoral fellow at the University of Minnesota. The SB system was originally developed for vertebrate genetics at the University of Minnesota, and my mentor's laboratory is a member of the Arnold and Mabel Beckman Center for Transposon Research. As a member of the Cancer Center, I have access to several Core facilities that will provide support to the projects proposed here. During my final year as a post-doctoral fellow, I will apply to assistant professor positions at Universities with strong research programs. My long-term career goal is to establish a research laboratory that uses novel genetic approaches to study human cancer biology and treatment. The proposed research employs a novel technology, the Sleeping Beauty transposon system, to identify genes involved in both cancer initiation and progression to therapy resistance. This research is relevant to human health as understanding the genetics of the disease is an important step toward developing more effective, patient-specific therapies. In addition, we hypothesize that this technology will be useful for creating better models of human cancer that will be useful for drug discovery and testing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01CA122183-04
Application #
7676779
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M1))
Program Officer
Lohrey, Nancy
Project Start
2006-09-18
Project End
2011-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
4
Fiscal Year
2009
Total Cost
$166,185
Indirect Cost
Name
University of Wisconsin Madison
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Bagley, Bruce N; Keane, Thomas M; Maklakova, Vilena I et al. (2012) A dominantly acting murine allele of Mcm4 causes chromosomal abnormalities and promotes tumorigenesis. PLoS Genet 8:e1003034
PĂ©rez-Mancera, Pedro A; Rust, Alistair G; van der Weyden, Louise et al. (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486:266-70
Wu, Xiaochong; Northcott, Paul A; Dubuc, Adrian et al. (2012) Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482:529-33
Bergerson, Rachel J; Collier, Lara S; Sarver, Aaron L et al. (2012) An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model. Blood 119:4512-23
Mattison, Jenny; Kool, Jaap; Uren, Anthony G et al. (2010) Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach. Cancer Res 70:883-95
Bender, Aaron M; Collier, Lara S; Rodriguez, Fausto J et al. (2010) Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas. Cancer Res 70:3557-65
Collier, Lara S; Adams, David J; Hackett, Christopher S et al. (2009) Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res 69:8429-37
Rahrmann, Eric P; Collier, Lara S; Knutson, Todd P et al. (2009) Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res 69:4388-97
Keng, Vincent W; Villanueva, Augusto; Chiang, Derek Y et al. (2009) A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 27:264-74
Largaespada, David A; Collier, Lara S (2008) Transposon-mediated mutagenesis in somatic cells: identification of transposon-genomic DNA junctions. Methods Mol Biol 435:95-108

Showing the most recent 10 out of 12 publications